Home Stock

Stock Research: Harmony Biosciences Holdings

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Harmony Biosciences Holdings

NasdaqGM:HRMY US4131971040
96
  • Value
    93
  • Growth
    80
  • Safety
    Safety
    52
  • Combined
    96
  • Sentiment
    86
  • 360° View
    360° View
    96
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on therapies for rare and other neurological diseases. Its main business is developing and commercializing treatments like WAKIX for narcolepsy, and investigational compounds like HBS-102, ZYN002, EPX-100, and EPX-200 for conditions such as Fragile X syndrome, 22q11.2 deletion syndrome, and epilepsy. The company operates in the pharmaceutical and neuroscience sectors, with product development primarily in neurological disease therapies. In the last fiscal year, the company had a market cap of $2010 million, profits of $558 million, and revenue of $715 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 96 (better than 96% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Harmony Biosciences Holdings are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for Harmony Biosciences Holdings. The consolidated Value Rank has an attractive rank of 52, which means that the share price of Harmony Biosciences Holdings is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 52% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 80, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 93. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 86. ...read more

more
Country USA
Industry Pharmaceuticals
Size Small
Website harmonybiosciences.com
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
52 32 34 17
Growth
80 91 51 100
Safety
Safety
93 86 43 43
Sentiment
86 96 83 100
360° View
360° View
96 98 34 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
26 40 17 81
Opinions Change
85 70 69 50
Pro Holdings
n/a 100 82 92
Market Pulse
79 83 95 90
Sentiment
86 96 83 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
52 32 34 17
Growth
80 91 51 100
Safety Safety
93 86 43 43
Combined
96 96 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
78 67 85 64
Price vs. Earnings (P/E)
54 41 31 28
Price vs. Book (P/B)
52 31 18 4
Dividend Yield
1 1 1 1
Value
52 32 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
72 74 82 81
Profit Growth
62 39 20 100
Capital Growth
97 97 91 94
Stock Returns
36 71 17 67
Growth
80 91 51 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
62 56 49 23
Refinancing
60 49 53 21
Liquidity
82 82 100 100
Safety Safety
93 86 43 43

Similar Stocks

Discover high‑ranked alternatives to Harmony Biosciences Holdings and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis
OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.